United Therapeutics Co. (NASDAQ:UTHR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of United Therapeutics Co. (NASDAQ:UTHR) have received a consensus rating of “Moderate Buy” from the fourteen analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $357.17.

UTHR has been the topic of several analyst reports. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. UBS Group raised their price target on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. TD Cowen upped their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. Finally, LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 25,000 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $833,350.26. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Raymond Dwek sold 5,000 shares of the stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $325.35, for a total value of $1,626,750.00. Following the completion of the sale, the director now owns 1,750 shares in the company, valued at $569,362.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 25,000 shares of United Therapeutics stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total value of $8,084,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $833,350.26. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,430 shares of company stock worth $37,204,602 in the last three months. 11.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its holdings in shares of United Therapeutics by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after purchasing an additional 22,978 shares during the period. LSV Asset Management lifted its position in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after buying an additional 436,851 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after buying an additional 22,683 shares during the period. Pacer Advisors Inc. grew its holdings in shares of United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after acquiring an additional 92,240 shares in the last quarter. Finally, Swedbank AB acquired a new position in shares of United Therapeutics in the first quarter worth $97,316,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.7 %

United Therapeutics stock opened at $359.57 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. United Therapeutics has a one year low of $208.62 and a one year high of $366.08. The company has a 50-day simple moving average of $348.11 and a 200-day simple moving average of $306.02. The firm has a market capitalization of $16.00 billion, a P/E ratio of 16.52, a P/E/G ratio of 1.29 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. During the same period in the previous year, the firm earned $5.24 earnings per share. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. As a group, equities analysts expect that United Therapeutics will post 24.71 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.